Validity of interferon-y-release assays for the diagnosis of @entity9178 in haemodialysis XXXX .

@entity1 @entity9178 @entity1062 @entity272 @entity378
Haemodialysis @entity1 are at higher risk of developing active @entity378 . However, @entity272 ( @entity272 ) have limitations and the diagnostic usefulness of interferon-y-release assays (IGRAs) remains unclear in immunocompromised hosts including haemodialysis @entity1 . Haemodialysis @entity1 were enrolled from a dialysis centre in Korea, an intermediate TB-burden country with a high bacille Calmette-Gu  rin (BCG) vaccination rate. The QuantiFERON-Gold TB In tube test (QFT) and the T-SPOT TB test (TSPOT) were performed, along with the @entity272 . We stratified @entity1 to low- and high-risk groups, according to the risk factors for @entity9178 . Association between each of the three diagnostic @entity1062 and the risk of @entity9178 was analysed. One hundred and sixty-seven @entity1 were enrolled. The positive rates for the @entity272 , the QFT and TSPOT were 23.5, 45.9 and 60.4%, respectively. Previous BCG vaccination increased the @entity272 -positive rate in the low-risk group (OR 4.438), whereas it affected neither QFT nor TSPOT. The positive QFT rates were 41.2 and 62.5% in the low- and high-risk groups, respectively. The QFT was associated with the high-risk group (OR 2.578), whereas the @entity272 was not. The positive TSPOT rates were 58.9 and 65.7% in the low- and high-risk groups, respectively. The frequency of indeterminate results was higher for the QFT (12.6%) compared with the TSPOT (4.8%). In conclusion, the IGRAs can be useful for the diagnosis of @entity9178 in haemodialysis @entity1 .
